Grant: Collaborative Research and Development Grants
University of Calgary
$117,900.00
Characterizing complex protein states with next generation HX-MS concepts
FY 2018-19
Summary
This proposal describes new concepts in hydrogen/deuterium exchange mass spectrometry (HX-MS) for characterizing highly-complex protein systems relevant to drug development activities in pharmaceutical research programs. HX-MS provides conformational data that link protein structure to protein function. Conceptually, HX processes offer an excellent opportunity to generate maps of structure-activity relationships and support the selection of leads in early stages of drug research. However, the complexity of available HX-MS technology has restricted its use in this context. Conventional solutions have low spectral capacity and under-developed data analysis routines, limiting HX-MS to simpler protein systems and low throughput. The research proposed here will overcome these barriers by developing a new, scalable nanoHX-MS^2 capability, supported by informatics solutions that evaluate the high volume of data for underlying structure-activity relationships. We will build on recent HX innovations from my laboratory, combined with new QTOF-based mass spectrometry technology from Sciex, a leading technology provider in the analytical instruments market. The major challenge for the research program will be to profile ultracomplex protein complexes or networks without loss of sequence coverage, and remove the need for manual intervention in both data collection and analysis. Through effective use of the MS^2 dimension, and the development of new processing reagents and informatics strategies, we anticipate a platform that can generate complete HX maps of protein states at least 10-fold more complex than current best capabilities. The platform will be developed with the active participation of pharmaceutical partners and benefit their drug development efforts. Pfizer will provide test scenarios in the form of complex protein-ligand systems, and Genentech will provide therapeutic proteins to support the development of a derivative mode of HX-MS^2 operation targeting the biologics market. Together, we anticipate that our research will address the key barriers to implementing HX-MS in a wider pharmaceutical R&D market, and shorten the path to commercializing systems, software and reagents.*
Program
Collaborative Research and Development Grants
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
486813-2015
Name nom
Schriemer, David
Department département
Biochemistry and Molecular Biology
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2015
Award amount
117900
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
3
Nb partie
3
Application title
Characterizing complex protein states with next generation HX-MS concepts
Keyword
NSERC
Application summary
This proposal describes new concepts in hydrogen/deuterium exchange mass spectrometry (HX-MS) for characterizing highly-complex protein systems relevant to drug development activities in pharmaceutical research programs. HX-MS provides conformational data that link protein structure to protein function. Conceptually, HX processes offer an excellent opportunity to generate maps of structure-activity relationships and support the selection of leads in early stages of drug research. However, the complexity of available HX-MS technology has restricted its use in this context. Conventional solutions have low spectral capacity and under-developed data analysis routines, limiting HX-MS to simpler protein systems and low throughput. The research proposed here will overcome these barriers by developing a new, scalable nanoHX-MS^2 capability, supported by informatics solutions that evaluate the high volume of data for underlying structure-activity relationships. We will build on recent HX innovations from my laboratory, combined with new QTOF-based mass spectrometry technology from Sciex, a leading technology provider in the analytical instruments market. The major challenge for the research program will be to profile ultracomplex protein complexes or networks without loss of sequence coverage, and remove the need for manual intervention in both data collection and analysis. Through effective use of the MS^2 dimension, and the development of new processing reagents and informatics strategies, we anticipate a platform that can generate complete HX maps of protein states at least 10-fold more complex than current best capabilities. The platform will be developed with the active participation of pharmaceutical partners and benefit their drug development efforts. Pfizer will provide test scenarios in the form of complex protein-ligand systems, and Genentech will provide therapeutic proteins to support the development of a derivative mode of HX-MS^2 operation targeting the biologics market. Together, we anticipate that our research will address the key barriers to implementing HX-MS in a wider pharmaceutical R&D market, and shorten the path to commercializing systems, software and reagents.*